SCHEMBL970429

SCHEMBL970429

CC(C)(C)[Si](C)(C)OCCOc1ccc2n[c]sc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
HSD17B10 Q99714 2/20 0.35
KMT2A Q03164 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
PPARA Q07869 1/20 0.33
LMNA P02545 2/20 0.32
TSHR P16473 2/20 0.32
TP53 P04637 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
DUT P33316 1/20 0.32
SCD O00767 1/20 0.31
CA4 P22748 1/20 0.30
NCF1 P14598 4/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9988353 0.80 ALDH1A1 (0.33) ALDH1A1HSD17B10KMT2ACASP1CASP7
SCHEMBL8014001 0.76 CA1 (0.49) ALDH1A1HSD17B10CA1CA2LMNA
SCHEMBL227271 0.76 KMT2A (0.53) ALDH1A1HSD17B10KMT2ACA1CA2
SCHEMBL10233638 0.76 CYP3A4 (0.61) ALDH1A1HSD17B10KMT2ACA1CA2
SCHEMBL970760 0.76 LTA4H (0.45) ALDH1A1LMNACYP1A2CYP2D6
SCHEMBL971555 0.74 DUT (0.34) CA1CA2DUT
SCHEMBL533470 0.71 CYP1A2 (0.49) ALDH1A1KMT2ALMNATSHRTP53
SCHEMBL973567 0.71 PDK2 (0.48) ALDH1A1PPARALMNACYP1A2CYP2D6
SCHEMBL973566 0.70 CA1 (0.42) ALDH1A1KMT2ACA1CA2PPARA
SCHEMBL13196947 0.70 KDM4E (0.42) ALDH1A1KMT2ACA1LMNANCF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131113-A1 PYRIDONE GLUCOKINASE ACTIVATORS HOFFMANN-LA ROCHE INC. (US) 2013-05-23 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8178689-B2 Tricyclic compounds HOFFMAN-LA ROCHE INC. (US) 2012-05-15 US disclosed
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
US-20110313002-A1 TRICYCLIC COMPOUNDS SARABU RAMAKANTH (US) 2011-12-22 US disclosed
US-20110021570-A1 PYRIDONE GLUCOKINASE ACTIVATORS HAYNES NANCY-ELLEN 2011-01-27 US disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131113-A1 PYRIDONE GLUCOKINASE ACTIVATORS GCK, PDXK, G6PD ALDH1A1 902/4885HSD17B10 837/4885KMT2A 3422/4885
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 ALDH1A1 1129/4885HSD17B10 1130/4885KMT2A 2072/4885
US-20110021570-A1 PYRIDONE GLUCOKINASE ACTIVATORS GCK, PDXK, G6PD ALDH1A1 902/4885HSD17B10 837/4885KMT2A 3422/4885
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK ALDH1A1 1059/4885HSD17B10 826/4885KMT2A 3040/4885
US-20110313002-A1 TRICYCLIC COMPOUNDS GPR119, PC, GOT2 ALDH1A1 545/4885HSD17B10 81/4885KMT2A 3535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.